📰 Ed Arce News
Ed Arce News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ed Arce. Real-time updates on events, politics, business and more.
June 24, 2024
Patrol this evening. We are still working to try to determine exactly how many people may have been involved and what their conditions are tonight. Back to you. All right, reporting live, thank you. The cruise ship that was slammed by a strong storm in the atlantic while in route from w jersey to florida is in port. The ship sailed into a major winter storm off of our coast on sunday. Powerful winds and waves as high as 30 feet tossed around the vessel. Royal caribbean Officials Say four apartme...
June 4, 2024
Raises Concerns Surrounding Lucien Selces Self-Serving Proposals and Lack of Credibility Glass Lewis Recommends that Aurinia Shareholders Vote FOR the Re-Election to the Board of Directors of All...
January 19, 2024
During the last three months, 7 analysts shared their evaluations of Travere Therapeutics (NASDAQ:TVTX), revealing diverse outlooks from bullish t...
December 5, 2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday.
November 15, 2023
Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today.
November 15, 2023
Operator: Ladies and gentlemen, good morning, and welcome to the Acurx Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
November 9, 2023
Operator: Welcome to the AcelRx third quarter 2023 financial results conference call.
October 18, 2023
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Universal Health (UHS – Research Report), Vik...
October 2, 2023
In a report released today, Ed Arce from H.C. Wainwright maintained Inventiva (IVA – Research Report) to a Buy, with a price target of $36...
September 27, 2023
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market trading.